| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
50 |
| Employees |
107 |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-186 |
| Cash Flow (TTM) (Millions $) |
-8 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Concert Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative medicines to treat patients who are suffering from serious diseases by applying its deuterium chemistry technology. Deuterium is a naturally occurring and stable isotope of hydrogen. This technology enables the company to create new chemical entities with potential advantages across a range of therapeutic areas, including oncology, central nervous system disorders, and inflammation, among others.
The company was founded in 2006 and is headquartered in Lexington, Massachusetts. Its portfolio includes several drug candidates that are either in preclinical or clinical development phases. Their lead program, CTP-543, is an oral drug candidate for the treatment of moderate-to-severe alopecia areata (AA), an autoimmune disease that affects hair growth. It has completed Phase 2a clinical trials and has demonstrated positive results in reducing the severity of AA symptoms.
Another program in concert pharmaceuticals is the AVP-786 program focuses on treating neurologic and psychiatric conditions, such as Alzheimer's disease, schizophrenia, and bipolar disorder. It is a combination of two compounds, dextromethorphan and quinidine. The combination is designed to treat symptoms associated with these conditions by targeting the overactive N-methyl-D-aspartate (NMDA) receptors within the brain.
Concert Pharmaceuticals also has a partnership with Celgene, a subsidiary of Bristol-Myers Squibb, to develop CTP-730, a deuterium-modified version of apremilast. It is an oral medication that works by inhibiting phosphodiesterase 4 (PDE4) and reducing inflammation. The drug is currently in Phase 1 clinical trials for the treatment of moderate-to-severe psoriasis.
The company's approach to drug development is unique and innovative, and it is focused on developing deuterium-modified compounds as a means of improving the properties of molecules to produce safer and more effective drugs. They have received several patents for their deuterium chemistry technology.
Overall, Concert Pharmaceuticals Inc. is a promising biopharmaceutical company with a diverse pipeline of drug candidates that have the potential to transform the treatment of several serious diseases. Its focus on deuterium chemistry technology sets it apart from other pharmaceutical companies and provides an innovative solution to improving drug efficacy and safety.
Company Address: 65 Hayden Avenue Lexington 2421 MA
Company Phone Number: 860-0045 Stock Exchange / Ticker: NASDAQ CNCE
|
%
11.46%